Daily Stock Analysis, DVAX, Dynavax Technologies Corp, priceseries

Dynavax Technologies Corp. Daily Stock Analysis
Stock Information
Open
5.56
Close
5.70
High
5.96
Low
5.52
Previous Close
5.56
Daily Price Gain
0.14
YTD High
12.42
YTD High Date
Jan 16, 2019
YTD Low
2.60
YTD Low Date
Jul 29, 2019
YTD Price Change
-3.75
YTD Gain
-39.74%
52 Week High
12.42
52 Week High Date
Jan 16, 2019
52 Week Low
2.60
52 Week Low Date
Jul 29, 2019
52 Week Price Change
-5.00
52 Week Gain
-46.78%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
4.05
Mar 14. 2017
5.76
12 Trading Days
42.11%
Link
LONG
Jun 1. 2017
5.65
Jul 5. 2017
9.63
23 Trading Days
70.41%
Link
LONG
Aug 30. 2017
17.20
Sep 26. 2017
20.60
18 Trading Days
19.78%
Link
LONG
Sep 28. 2017
21.25
Oct 12. 2017
22.41
10 Trading Days
5.45%
Link
LONG
Mar 20. 2018
17.45
Apr 2. 2018
18.84
8 Trading Days
7.99%
Link
LONG
Jan 4. 2019
9.81
Jan 23. 2019
11.05
12 Trading Days
12.67%
Link
LONG
Aug 7. 2019
2.99
Aug 27. 2019
4.15
14 Trading Days
38.80%
Link
LONG
Oct 21. 2019
4.27
Nov 7. 2019
4.98
13 Trading Days
16.61%
Link
Company Information
Stock Symbol
DVAX
Exchange
NasdaqCM
Company URL
http://www.dynavax.com
Company Phone
5108485100
CEO
Eddie J. Gray
Headquarters
California
Business Address
2929 SEVENTH STREET, SUITE 100, BERKELEY, CA 94710
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001029142
About

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor biology to discover and develop novel vaccines and therapeutics. The company's development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company's other products under pipeline are SD-101, DV1179 Autoimmune Disease and AZD1419 Asthma Therapy. Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Description

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.